These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 27462088)

  • 1. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
    Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
    J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
    Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
    J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Relevance of Sex in the Association of Synthetic Cannabinoid Use With Psychosis and Agitation in an Inpatient Population.
    Bassir Nia A; Mann CL; Spriggs S; DeFrancisco DR; Carbonaro S; Parvez L; Galynker II; Perkel CA; Hurd YL
    J Clin Psychiatry; 2019 Jul; 80(4):. PubMed ID: 31265768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
    Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
    Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Psychopathologic differences between cannabis-induced psychoses and recent-onset primary psychoses with abuse of cannabis.
    Rubio G; Marín-Lozano J; Ferre F; Martínez-Gras I; Rodriguez-Jimenez R; Sanz J; Jimenez-Arriero MA; Carrasco JL; Lora D; Jurado R; López-Trabada JR; Palomo T
    Compr Psychiatry; 2012 Nov; 53(8):1063-70. PubMed ID: 22682680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosis and synthetic cannabinoids.
    Deng H; Verrico CD; Kosten TR; Nielsen DA
    Psychiatry Res; 2018 Oct; 268():400-412. PubMed ID: 30125871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cannabis, cannabinoids, and health.
    Lafaye G; Karila L; Blecha L; Benyamina A
    Dialogues Clin Neurosci; 2017 Sep; 19(3):309-316. PubMed ID: 29302228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthetic cannabinoid JWH-018 and psychosis: an explorative study.
    Every-Palmer S
    Drug Alcohol Depend; 2011 Sep; 117(2-3):152-7. PubMed ID: 21316162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects.
    van Amsterdam J; Brunt T; van den Brink W
    J Psychopharmacol; 2015 Mar; 29(3):254-63. PubMed ID: 25586398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delusions incorporating cannabis use in dually diagnosed patients with a primary psychotic disorder.
    Flanders SE
    Aust N Z J Psychiatry; 2007 Nov; 41(11):934-6. PubMed ID: 17924247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis use and psychotic disorders: an update.
    Hall W; Degenhardt L; Teesson M
    Drug Alcohol Rev; 2004 Dec; 23(4):433-43. PubMed ID: 15763748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabis use in psychotic patients.
    Sembhi S; Lee JW
    Aust N Z J Psychiatry; 1999 Aug; 33(4):529-32. PubMed ID: 10483847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of sex on substance use between first episode psychosis patients and healthy people.
    Núñez C; Ochoa S; Huerta-Ramos E; Baños I; Barajas A; Dolz M; Sánchez B; Del Cacho N; ; Usall J
    Compr Psychiatry; 2016 Aug; 69():169-78. PubMed ID: 27423358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia.
    Arendt M; Mortensen PB; Rosenberg R; Pedersen CB; Waltoft BL
    Arch Gen Psychiatry; 2008 Nov; 65(11):1269-74. PubMed ID: 18981338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis and Neuropsychiatry, 2: The Longitudinal Risk of Psychosis as an Adverse Outcome.
    Andrade C
    J Clin Psychiatry; 2016 Jun; 77(6):e739-42. PubMed ID: 27337422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A community survey of adverse effects of cannabis use.
    Thomas H
    Drug Alcohol Depend; 1996 Nov; 42(3):201-7. PubMed ID: 8912803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cannabis and psychosis: search of a causal link through a critical and systematic review].
    Le Bec PY; Fatséas M; Denis C; Lavie E; Auriacombe M
    Encephale; 2009 Sep; 35(4):377-85. PubMed ID: 19748375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Characteristics of Synthetic Cannabinoid Use in a Large Urban Psychiatric Emergency Setting.
    Manseau MW; Rajparia A; Joseph A; Azarchi S; Goff D; Satodiya R; Lewis CF
    Subst Use Misuse; 2017 May; 52(6):822-825. PubMed ID: 28156305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
    Winstock A; Lynskey M; Borschmann R; Waldron J
    J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis.
    Boydell J; Dean K; Dutta R; Giouroukou E; Fearon P; Murray R
    Schizophr Res; 2007 Jul; 93(1-3):203-10. PubMed ID: 17462864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.